Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer
Ovarian tumors create a dynamic microenvironment that promotes angiogenesis and reduces immune responses. Our research has revealed that threonyl-tRNA synthetase (TARS) has an extracellular angiogenic activity separate from its function in protein synthesis. The objective of this study was to test the hypothesis that TARS expression in clinical samples correlates with angiogenic markers and ovarian cancer progression.
Protein and mRNA databases were explored to correlate TARS expression with ovarian cancer. Serial sections of paraffin embedded ovarian tissues from 70 patients diagnosed with epithelial ovarian cancer and 12 control patients were assessed for expression of TARS, vascular endothelial growth factor (VEGF) and PECAM using immunohistochemistry. TARS secretion from SK-OV-3 human ovarian cancer cells was measured. Serum samples from 31 tissue-matched patients were analyzed by ELISA for TARS, CA-125, and tumor necrosis factor-α (TNF-α).
There was a strong association between the tumor expression of TARS and advancing stage of epithelial ovarian cancer (p < 0.001). TARS expression and localization were also correlated with VEGF (p < 0.001). A significant proportion of samples included heavy TARS staining of infiltrating leukocytes which also correlated with stage (p = 0.017). TARS was secreted by ovarian cancer cells, and patient serum TARS was related to tumor TARS and angiogenic markers, but did not achieve significance with respect to stage. Multivariate Cox proportional hazard models revealed a surprising inverse relationship between TARS expression and mortality risk in late stage disease (p = 0.062).
TARS expression is increased in epithelial ovarian cancer and correlates with markers of angiogenic progression. These findings and the association of TARS with disease survival provide clinical validation that TARS is associated with angiogenesis in ovarian cancer. These results encourage further study of TARS as a regulator of the tumor microenvironment and possible target for diagnosis and/or treatment in ovarian cancer.
KeywordsTumor microenvironment Angiogenesis tRNA synthetase Serous papillary ovarian cancer Database analysis Multivariate Cox analysis
Vascular endothelial growth factor
Platelet endothelial cell adhesion molecule
Enzyme-linked immunosorbent assay
Hypoxia inducible factor
Tumor necrosis factor-α
amino-acyl tRNA synthetase
Although mortality rates have decreased for most gynecologic malignancies, ovarian cancer remains the most lethal gynecologic cancer and ranks fifth in cancer deaths among women . Critical issues contributing to poor prognosis include the inability to detect early stage disease and the capacity of ovarian cancer cells to manipulate the tumor microenvironment [2, 3, 4]. The current serum biomarker cancer antigen-125 (CA-125) is not a reliable indicator of ovarian cancer in pre-menopausal women and its use in combination with other screening techniques has not improved survival .
Ovarian cancer is highly angiogenic, and our laboratory and others have correlated ovarian cancer progression with the expression of angiogenic signaling molecules, including hypoxia-inducible factor (HIF-1α) and vascular endothelial growth factor (VEGF) [6, 7]. A continuing theme in effective angiogenesis is the importance of secreted cytokines including tumor necrosis factor-α (TNF-α) that exert both autocrine and paracrine effects on inflammatory and vascular endothelial cells . This interaction network of secreted factors holds important clues for future diagnostic and treatment targets. It is therefore critical to continue advances in understanding the underlying cell signaling associated with the developing ovarian cancer microenvironment.
The study of threonyl tRNA-synthetase (TARS) as an extracellular angiogenic factor was instigated by the observation that the TARS inhibitor borrelidin has an anti-angiogenic effect . Although the canonical function of TARS is to charge threonine onto tRNA during protein synthesis, it has been identified as an auto-antibody (PL-7) target in myositis autoimmune disorders . The etiology of these diseases includes TNF-α signaling, and there is an epidemiological linkage between myositis and several different cancers [11, 12]. Moreover, we recently discovered that TARS has direct extracellular angiogenic activity both in vitro and in vivo through a mechanism that includes attraction of endothelial cells . These lines of evidence led to the hypothesis that TARS plays a role in the tumor microenvironment and may be an indicator of progression in angiogenic and/or inflammatory cancers.
Here we explored the relationship between TARS and human ovarian cancer. We provide the first report that levels of TARS in patient tumors and inflammatory cells correlate with angiogenesis and stage of disease. The secretion of TARS by ovarian cancer cells, its presence within patient serum, and the negative relationship between tumor TARS and mortality risk highlight the potential of TARS as a target in the clinical management of ovarian cancer.
The SAGE anatomic viewer within the Cancer Gene Anatomy Project database (CGAP) (http://cgap.nci.nih.gov/SAGE/Viewer?TAG=GCAGACATTG&CELL=0&ORG=Hs&METHOD=SS10,LS10) was used to assess mRNA expression levels of TARS within normal and malignant tissues. The Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geoprofiles/40739453) was used to search existing mRNA profiles related to ovarian cancer patient studies . The Human Protein Atlas (http://www.proteinatlas.org/ENSG00000113407/cancer) provided information about TARS and cancers within a set of immunostained tissue arrays .
Ovarian patient study group
This research was approved by the University of Vermont’s institutional review board (CHRMS 00–260, 01–026, 12–004). Written informed consent for participation in the study was obtained from all patients. The study group consisted of 70 patients diagnosed with epithelial ovarian cancer at Fletcher Allen Health Care/University of Vermont between 1999 and 2003. The control group consisted of 12 women who underwent oophorectomies that were identified as benign pathologies (See Additional file 1: Table S1A). Ovarian tissue samples were fixed with formalin and embedded in paraffin. Histological subtype was according to the WHO classification and stage was determined by FIGO criteria. Blood samples were obtained from a subset of patients (6 control, 31 cancer) prior to surgery (See Additional file 1: Table S1B). Serum was prepared by centrifugation and then cryopreserved until use. Patient survival information was obtained using the Fletcher Allen electronic health record system (PRISM).
Serial sections (5 μm) from each paraffin-embedded specimen were cut, transferred to slides, and then analyzed using immunohistochemistry to measure the expression of TARS, VEGF and PECAM (CD31) as in Wong et al. . Immunoperoxidase staining was performed using the following antibodies: monoclonal anti-TARS (1:100 Novus, NB H00006897-M01, clone 1A9), monoclonal anti-VEGF (1:100 Santa Cruz Biotechnology, SC-7269), and monoclonal anti-PECAM (1:40 anti-CD31, DAKO, M-0823). No primary antibody was used as a negative control. TARS antibody staining was optimized for the greatest range of detection by testing multiple dilutions (1:50–1:300) using benign and Stage 3 ovarian tumor sections. Secondary antibody was DAKO Polymer–HRP goat anti-mouse IgG. Cells were lightly counterstained with Mayers’ hematoxylin and slides were dehydrated and then mounted using Cytoseal-60. Images were obtained using an Olympus BX50 light microscope coupled to a CCD camera and Metamorph image capture software. For TARS and VEGF, images were scored blindly by 2 different investigators for expression level using a scale of 1–4, where 1 was no staining and 4 was intense staining.
Cultured cell experiments
SK-OV-3 human ovarian cancer cells were cultured in McCoy’s media supplemented with 10% fetal bovine serum as described in . For secretion experiments, cells were grown in 10 cm dishes and serum-starved for 24 h followed by treatment with 10 ng/ml TNF-α or exposure to 2% O2 for 16 h. Media was collected and concentrated 20-fold using Amicon® Ultra-4 centrifugal filters. Cell membrane integrity was confirmed using the lactate dehydrogenase assay CytoTox-ONE™. Cell lysates (5%) and corresponding concentrated cell media (25%) were separated by SDS-PAGE and analyzed by Western blot for presence of TARS (1:1000 rabbit-anti-ThrRS, Santa Cruz Biotechnology SC-98543) as described in . β-tubulin was detected as a loading control for the lysates and to confirm that TARS found in the media was not a result of cell lysis.
To measure relative mRNA levels, SK-OV-3 cells were grown in 6-well dishes. After treatments, mRNA was extracted and purified using a Qiagen RNeasy® kit. Double stranded cDNA was generated and relative mRNA levels were quantified by RT-qPCR using Taqman® Assays on Demand™ for TARS, VEGF, and interleukin-1β (IL-1β) with β2 microglobulin as the reference gene (Applied Biosystems). Values were determined by the comparative CT method and presented as Rq (2ΔΔCT).
ELISA was performed on 50 μl of SK-OV-3 cell media or patient serum samples using commercially available reagents to measure human TARS (Cusabio Biotech) or TNF-α (R&D Systems Quantikine® HS ELISA). Values were determined by comparing to a standard curve (0–800 pg/ml for TARS, 0–32 pg/ml for TNF-α).
Statistical analysis was performed using SYSTAT software. Significance between group averages was determined by one way ANOVA followed by pair-wise multiple comparisons. Equal variance within the datasets was confirmed by Bartlett Chi-square analysis. Relationships between variables were examined using Pearson correlations. Cox proportional hazard models were used to analyze survival outcomes. Multivariate Cox models were also generated to consider the effects of stage grouping and year of diagnosis on the outcome.
Database analysis of TARS expression in ovarian cancer
TARS expression in patient tumor samples is positively correlated with stage of disease and angiogenic markers
Pearson Correlation Matrix for TARS expression in ovarian cancer patient samples
TARS is overexpressed in infiltrating leukocytes within ovarian tumors
In the process of scoring the tumor tissue, we observed that many tumors (32 of 70) exhibited positive TARS staining in the cytoplasm of infiltrating leukocytes (Figure 3). These cells were histologically identified as neutrophils and plasma cells due to their chromatin characteristics (See Additional file 3B). A significant correlation was found between leukocyte TARS staining and both tumor TARS and stage of disease (p = 0.017), however the regression coefficients were weaker and the association with VEGF was not significant (Table 1). In light of the connection between TARS and immune responses, these data may indicate a role for TARS in the immune cell response to ovarian tumors.
TARS is secreted from ovarian cancer cells in response to cell stress
Serum levels of TARS correlate with tumor levels of TARS
Because of the link between TNF-α and TARS secretion by cultured ovarian cancer cells as well as the TNF-α association with myositis, we predicted that the serum levels for TARS would parallel those for TNF-α. The TNF-α levels ranged from 0.145-12.0 pg/ml and levels did not correlate with stage of disease or level of TARS in tumors or serum (Table 1). When compared with other cancer patient studies, the levels of TNF-α in our study were lower in both controls and cancer patients . Thus, although no correlations were found between TNF-α and TARS or ovarian cancer, more studies are needed using additional samples to account for variability and low levels of detection.
Overexpression of TARS correlates with increased survival in late-stage disease
Hazard ratios for the association of TARS with mortality using univariate Cox proportional hazard models
CA - 125
TARS ( pg / ml )
Multivariate Cox proportional hazard model for TARS tumor score
Hazard ratio (95% CI)
Stage grouping (0–2, 3, 4)
Year of Dx (1998–2001)
The goal of this study was to determine if there is a clinical relationship between TARS and the progression and angiogenic potential of human ovarian cancer. The data reveal the first positive correlation between TARS tumor expression and the progression of cancer. The overall results of the evaluation of TARS in tumor, immune cells, and serum provide strong support for a connection between TARS and both angiogenesis and stage of ovarian cancer. Furthermore, these data provide clinical relevance to our previous biologic observations of an angiogenic function of TARS. The observed secretion of TARS by ovarian cancer cells leads to a working model for TARS signaling that includes stress-mediated release of TARS that stimulates angiogenesis and alters the ovarian tumor microenvironment.
TARS is a member of the aaRS enzyme family whose primary function is to catalyze ATP-dependent formation of specific amino-acyl tRNAs, thus maintaining fidelity during protein translation . Several aaRSs have been associated with non-canonical cell signaling related to inflammation, cell migration, and angiogenesis [24, 25, 26, 27, 28, 29, 30]. Those aaRSs associated with angiogenesis include tyrosyl-tRNA synthetase, which exhibits extracellular angiogenic activity, and seryl-tRNA synthetase, which acts in the nucleus to regulate VEGF expression during vascular development [26, 29]. Unlike TARS, these aaRSs were not upregulated in ovarian cancer according to the mRNA or protein database analyses. The selective association of TARS with ovarian cancer suggests that its extracellular activity may be specifically important in the regulation of the ovarian tumor microenvironment.
Angiogenesis has emerged as a critical component of the tumor microenvironment, and anti-angiogenic therapies for cancers have had success due to the reliance of many cancers on new vessels and the poor prognosis associated with cancers that have advanced angiogenesis . Anti-angiogenic therapies for ovarian cancer have shown effectiveness in clinical trials using the VEGF inhibitor bevacizumab, especially when combined with the standard chemotherapy regimen (paclitaxel and carboplatin) . Although these therapies have benefitted patients with ovarian cancer, treatment complications and lack of success in some patients demonstrate a clear need for more ovarian-specific angiogenic targets. We propose that TARS is an important angiogenic molecule that exhibits extracellular signaling in ovarian cancer cells only under conditions of metabolic stress. An agent that exclusively targets extracellular TARS thus has the potential to provide an anti-cancer therapy that is effective and more specific than existing treatments.
The finding that TARS is secreted by ovarian cancer cells in response to stress signaling is supported by the Exocarta proteomics database, where TARS is on the list of exosomal proteins released from bladder cancer cells, and ovarian cancer cells [33, 34]. An exosome mechanism for TARS secretion would be consistent with other signaling proteins that regulate the extracellular matrix and are overexpressed in cancer including heat shock protein 90 (HSP90), plasminogen activator inhibitor-1 (PAI-1) and caveolin-1 (cav-1) [35, 36, 37]. Although the correlation between serum TARS and stage of disease failed to reach significance, its presence at detectable levels and trend with TARS tumor levels indicate that it has potential value as an ovarian cancer diagnostic.
Two unexpected discoveries were the findings that TARS is overexpressed in infiltrating leukocytes within ovarian tumors and that mortality risk is slightly reduced for patients with high expression of TARS within their tumors. TARS has previously been associated with autoimmune disorders because it is the target for the autoantibody PL-7 in myositis disorders . A specific role for TARS in immune cell signaling has not been reported, however several other aaRS enzymes exert immune cell functions  and TARS is among B cell proteins secreted in exosomes . It is possible that the improved survival associated with TARS expression is related to its effects on inflammatory cell signaling that reduce the support of the microenvironment. This possibility is supported by evidence that infiltrating immune cells in the context of high vascularity improves survival in high grade serous ovarian cancer . Alternatively, the signaling through TARS may improve the susceptibility of tumors to chemotherapy, similar to the improved response of ovarian tumors expressing p53 mutations . The antigenic properties of TARS and the known role for immune cell signaling in angiogenesis encourage future study of TARS in immune cell responses to ovarian tumors.
Taken together, the results of this study demonstrate that TARS expression is significantly increased in human epithelial ovarian cancer and relates to angiogenic markers and stage of disease. Opposing correlations of TARS with stage vs. survival suggest a complex role for TARS in tumor progression. We propose that TARS is secreted by tumor cells in response to metabolic stress or cytokine signaling, which then affects the microenvironment through vascular endothelial and immune cell responses. The limitations of this study include the number of patient samples and the IHC scoring technique. These weaknesses are balanced by the strength of the information for each patient and the ability to distinguish tumor staining within sections. The selectivity of TARS overexpression in ovarian cancer and its presence in patient serum samples encourages further study of TARS as a diagnostic or therapeutic target.
The authors wish to recognize Sean Bullis for his assistance in retrieving patient information for the statistical analysis. Images were obtained using facilities within the Microscopy Imaging Center of the UVM College of Medicine. The RT-qPCR was performed by the VT Cancer Center DNA Analysis Facility of the UVM College of Medicine. This research was primarily supported by grants from the Marsha Rivkin Center for Ovarian Cancer Research, the Lake Champlain Cancer Resource Organization and the UVM College of Medicine. TW was supported by the Totman Medical Research Trust Fund. CF contributions were supported by NIGMS 2R01GM54899.
- 1.Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR: Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev. 2011, 11 (10): 719-725. 10.1038/nrc3144.CrossRefGoogle Scholar
- 5.Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011, 104 (5): 863-870. 10.1038/sj.bjc.6606092.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR, Australian Ovarian Cancer Study G: A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012, 72 (1): 66-75. 10.1158/0008-5472.CAN-11-2178.CrossRefPubMedGoogle Scholar
- 10.Howard OMZ, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, HÃ¤rtlein M, Kron M, Yang D, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ: Histidyl-tRNA Synthetase and Asparaginyl-tRNA Synthetase, Autoantigens in Myositis, Activate Chemokine Receptors on T Lymphocytes and Immature Dendritic Cells. J Exp Med. 2002, 196 (6): 781-791. 10.1084/jem.20020186.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Williams TF, Mirando AC, Wilkinson B, Francklyn CS, Lounsbury KM: Secreted Threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis. Nat Sci Reports. 2013, 3: 1317-Google Scholar
- 19.Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013, 24 (6): 751-765. 10.1016/j.ccr.2013.10.013.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Park MC, Kang T, Jin D, Han JM, Kim SB, Park YJ, Cho K, Park YW, Guo M, He W, Yang X-L, Schimmel P, Kim S: Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. PNAS. 2012, 109 (11): E640-E647. 10.1073/pnas.1200194109.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Leclerc P, Jibard N, Meng X, Schweizer-Groyer G, Fortin D, Rajkowski K, Kang K, Catelli MG, Baulieu EE, Cadepond F: Quantification of the nucleocytoplasmic distribution of wild type and modified proteins using confocal microscopy: interaction between 90-kDa heat shock protein (Hsp90 alpha) and glucocorticosteroid receptor (GR). Exp Cell Res. 1998, 242 (1): 255-264. 10.1006/excr.1998.4117.CrossRefPubMedGoogle Scholar
- 36.Hamaguchi E, Takamura T, Shimizu A, Nagai Y: Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. JPET. 2003, 307 (3): 987-994. 10.1124/jpet.103.054346.CrossRefGoogle Scholar
- 39.Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ: Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. PloS one. 2013, 8 (12): e82406-10.1371/journal.pone.0082406.CrossRefPubMedPubMedCentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/620/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.